These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20702967)

  • 1. [Do orally active factor Xa (FXa) inhibitors have potential as innovative new anticoagulants? Future perspective from preclinical data].
    Konishi N; Hiroe K; Kawamura M
    Nihon Yakurigaku Zasshi; 2010 Aug; 136(2):88-92. PubMed ID: 20702967
    [No Abstract]   [Full Text] [Related]  

  • 2. New oral anticoagulants: should they replace heparins and warfarin?
    Tsiara S; Pappas K; Boutsis D; Laffan M
    Hellenic J Cardiol; 2011; 52(1):52-67. PubMed ID: 21292607
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
    Meddahi S; Samama MM
    J Mal Vasc; 2014 May; 39(3):183-94. PubMed ID: 24650612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The promise of novel direct oral anticoagulants.
    Hoffman R; Brenner B
    Best Pract Res Clin Haematol; 2012 Sep; 25(3):351-60. PubMed ID: 22959551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New anticoagulants for the prevention of thromboembolism.
    Lepic K; Crowther M
    Curr Pharm Des; 2010; 16(31):3472-4. PubMed ID: 20858184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New oral anticoagulants in the management of venous thromboembolism: a major advance?
    Sciascia S; Hunt BJ
    Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):487-8. PubMed ID: 25150440
    [No Abstract]   [Full Text] [Related]  

  • 7. ["Xa-tra-xa": opportunities and open questions about new anticoagulants].
    Beer JH
    Praxis (Bern 1994); 2011 Aug; 100(16):947. PubMed ID: 21910293
    [No Abstract]   [Full Text] [Related]  

  • 8. [Large studies of NOAC shows good and safe stroke protection].
    Hijazi Z; Oldgren J
    Lakartidningen; 2015 Sep; 112():. PubMed ID: 26348046
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
    Eriksson BI; Quinlan DJ; Eikelboom JW
    Annu Rev Med; 2011; 62():41-57. PubMed ID: 21226611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
    Morell J; Sullivan B; Khalabuda M; McBride BF
    J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New oral anticoagulants for acute venous thromboembolism.
    Med Lett Drugs Ther; 2014 Jan; 56(1433):3-4. PubMed ID: 24419296
    [No Abstract]   [Full Text] [Related]  

  • 12. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.
    Sattari M; Lowenthal DT
    Am J Ther; 2011 Jul; 18(4):332-8. PubMed ID: 20535013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: 'Re. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of VTE: A Systematic Review and Meta-analysis of Phase III Trials'.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):127. PubMed ID: 25882231
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: 'Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
    Spanos K; Giannoukas AD
    Eur J Vasc Endovasc Surg; 2015 Mar; 49(3):353. PubMed ID: 25556084
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: 'Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'- Key Learning Points for Surgeons.
    Hurst KV; Lee R; Milosevic I; Handa A
    Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):126-7. PubMed ID: 25933476
    [No Abstract]   [Full Text] [Related]  

  • 17. Response to 'Re: Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
    Kakkos SK; Kirkilesis GI; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2015 Mar; 49(3):353-4. PubMed ID: 25556083
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of factor Xa inhibitors in venous thromboembolism treatment.
    Cabral KP; Ansell JE
    Vasc Health Risk Manag; 2015; 11():117-23. PubMed ID: 25673997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advantages and limitations of the new anticoagulants.
    Schulman S
    J Intern Med; 2014 Jan; 275(1):1-11. PubMed ID: 24112453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
    Ufer M
    Thromb Haemost; 2010 Mar; 103(3):572-85. PubMed ID: 20135071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.